Cancer-Killing virus and immune drug combo tested in advanced tumors – study halted early
NCT ID NCT06063317
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new treatment for adults with advanced solid tumors that had not responded to standard therapies. The treatment combined a cancer-killing virus (onCARlytics) with an immune-boosting drug (blinatumomab), given either into the tumor or through a vein. The study aimed to check safety and find the best dose, but it was terminated early, so only limited safety data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
onCARlytics (CF33-CD19) and blinatumomab
What this could lead to
If successful, this approach could point toward a new way to treat advanced solid tumors by using a virus to target cancer cells and an immune therapy to boost the body's attack.
What could go wrong
This was a very early (Phase 1) study that was terminated, so results are limited. The combination may cause serious side effects, and it is unknown if it will shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Northwestern
Chicago, Illinois, 60208, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15219, United States